<DOC>
	<DOCNO>NCT01256723</DOCNO>
	<brief_summary>The main purpose study observe incidence major adverse cardiac cerebrovascular event ( MACCE ) , target vessel failure ( TVF ) , target vessel revascularization ( TVR ) stent thrombosis 5 year procedure patient underwent percutaneous coronary intervention ( PCI ) everolimus-eluting stent unprotected leave main coronary artery ( ULMCA ) disease lesion involve ULMCA Japan . The investigator also establish method adjustment Japanese version SYNTAX score conduct assessment use SYNTAX score recently report US Europe well EuroSCORE , clarify difference PCI procedure treatment result Japan report US Europe .</brief_summary>
	<brief_title>Japan Unprotected Left Main Coronary Artery Disease Percutaneous Coronary Intervention ( PCI ) Strategy On New Generation Stents</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patients age 20 year old 2 . Patients sign write consent 3 . Patients indicate percutaneous coronary intervention ( PCI ) 4 . Patients consider eligible drug elute stent 5 . Patients de novo lesion treat 6 . Patients ULMCA lesion involve ULMCA 7 . Patients treat two long everolimuseluting stent one branch 8 . Patients receive antiplatelet agent least 12 month placement drug elute stent 1 . Patients fully understand content inform consent study 2 . Patients provide informed consent mental retardation language disorder 3 . Patients follow 2 year completion stent placement 4 . Patients previously receive PCI coronary artery bypass graft ( CABG ) leave main coronary artery ( LMCA ) disease 5 . Patients schedule undergo cardiac surgery 6 . Patients enrol ongoing registry clinical trial . Except postmarketing study ( PMS ) influence result study 7 . In principal , patient participate scheduled participate another clinical trial related cardiac blood vessel completion 2year followup period study 8 . Patients life expectancy le 3 year concomitant disease enrollment 9 . Patients home oxygen therapy ( HOT ) 10 . Patients serious valvular disease 11 . Patients dialysis treatment 12 . Patients severe renal dysfunction ( serum creatinine â‰¥ 2.0 mg/dL ) 13 . Patients low leave ventricular ejection fraction le 30 % 14 . Patients acute myocardial infarction CK ( CPK ) level exceed twice institutional upper limit normal 15 . Patients chronic total occlusion ( CTO ) LMCA 16 . Patients consider require protection device 17 . Patients confirm allergy hypersensitivity everolimus , acrylic polymer , fluoropolymer cobalt chrome alloy L605 18 . Patients side effect antiplatelet agent anticoagulant 19 . Nursing woman childbearing potential whose pregnancy test conduct within 14 day procedure positive 20 . Patients disqualified participation investigator/subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>drug elute stent ( DES )</keyword>
	<keyword>unprotected leave main coronary artery ( ULMCA )</keyword>
</DOC>